Home > Insider Trading > Filing (0001209191-17-065094)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1242825	M Jeffrey Leiden	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Ceo & President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-12-11	20,090	$140.31	237,407	No	4	S	Direct
Common Stock	Disposition	2017-12-11	87,578	$141.35	149,829	No	4	S	Direct
Common Stock	Disposition	2017-12-11	12,134	$142.21	137,695	No	4	S	Direct
Common Stock	Disposition	2017-12-11	5,198	$143.39	132,497	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	440	Indirect	401(k)

Footnotes

Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $140.31 (range $139.85 to 140.84).
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $141.35 (range $140.86 to $141.85).
Open market sales reported on this line occurred at a weighted average price of $142.21 (range $141.86 to $142.79).
Open market sales reported on this line occurred at a weighted average price of $143.39 (range $142.90 to $143.85).